Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Potential clinical value of circulating chromogranin A in patients with prostate carcinoma.

Annals of oncology : official journal of the European Society for Medical Oncology - 1 Jan 2001

Berruti A, Dogliotti L, Mosca A, Gorzegno G, Bollito E, Mari M, Tarabuzzi R, Poggio M, Torta M, Fontana D, Angeli A

Abstract excerpt

BACKGROUND: Neuroendocrine (NE) differentiation of prostate adenocarcinoma has received increasing attention in recent years as a result of possible implications for prognosis and therapy. The presence of NE tumor subpopulation can be gauged non invasively by measuring circulating levels of secretory products, primarily chromogranin A (CgA). METHODS: This article provides a review on published papers evaluating...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Androgen Antagonists
Share to Carcinoma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cell Differentiation

Share to Chromogranin A

Share to Chromogranins

Share to Neurosecretory Systems

Share to Prostate-Specific Antigen

Share to Prostatic Neoplasms

Source

Identifiers

PMID: 11762344
DOI: 10.1093/annonc/12.suppl_2.s153

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 11 closest

Potential clinical value of circulating chromogranin A in patients with prostate carcinoma.PMID 11762344Read ↗

The neuroendocrine phenotype in prostate cancer: basic and clinical aspects.Semantic proximity Read ↗

Skewing towards neuroendocrine phenotype in high grade or high stage androgen-responsive primary prostate cancer.Semantic proximity Read ↗

Elevated serum progastrin-releasing peptide (31-98) in metastatic and androgen-independent prostate cancer patients.Semantic proximity Read ↗

Neuroendocrine differentiation in human prostate cancer. Morphogenesis, proliferation and androgen receptor status.Semantic proximity Read ↗

Anterior gradient 2 (AGR2): blood-based biomarker elevated in metastatic prostate cancer associated with the neuroendocrine phenotype.Semantic proximity Read ↗

Adrenomedullin, an autocrine/paracrine factor induced by androgen withdrawal, stimulates 'neuroendocrine phenotype' in LNCaP prostate tumor cells.Semantic proximity Read ↗

Transdifferentiation of prostate cancer cells to a neuroendocrine cell phenotype in vitro and in vivo.Semantic proximity Read ↗

Neuroendocrine differentiation in prostatic carcinoma.Semantic proximity Read ↗

Acquisition of neuroendocrine characteristics by prostate tumor cells is reversible: implications for prostate cancer progression.Semantic proximity Read ↗

Neuroendocrine cells in tumour growth of the prostate.Semantic proximity Read ↗

Neuroendocrine immunophenotype as predictor of clinical recurrence in 110 patients with prostate cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.